^
Association details:
| Biomarker: | Chr t(11;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Xpovio (selinexor) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Published date:
10/19/2022
Excerpt:
Here, we report that in four patients with multiple myeloma with t(11;14), the concomitant administration of venetoclax and selinexor was safe and associated with disease response...These data suggest that the combination of venetoclax and selinexor is effective and t(11;14) may serve as a therapeutic marker for response and target for future clinical trials.
DOI:
10.1038/s41698-022-00315-2
Source:
Title:
4067 / 21 - Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Published date:
03/09/2022
Excerpt:
...two patients with relapsed, refractory t(11;14) MM and disease progression after multiple lines of therapy were treated with venetoclax; however, after initial response, they developed resistance and progressive disease. Based off our preclinical results, selinexor was added to venetoclax and recaptured responses (VGPR and MR, respectively) suggesting a beneficial effect of the combination over single agent venetoclax.
